Seeking Alpha

Chemistfrog's  Instablog

Chemistfrog
Send Message
My name is Stephen. I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has... More
My company:
Chemistfrog on Twitter
My blog:
Chemistfrog Blog, Stock Picks, Alerts and Company Due Diligence!!
  • Eisai's Phase III Trial Failure of Sepsis Drug Presents Opportunity for Cytosorbents Corp 5 comments
    Jan 25, 2011 11:05 PM | about stocks: ESALY

    On January 25th Japan's Eisai announced that it scrapped its late phase III trial of its blockbuster-potential drug Eritoran after results indicated that its sepsis reduction potential data turned out to be no better than a placebo.  This is more than a minor setback for a drug touted to have potentially $2 billion in sales per Atsushi at Barclay’s.

     As Cytosorbent (OTCBB: CTSO) investors eagerly await the completion of Cytosorbent’s own blockbuster potential sepsis device, one can view the 3-month chart and its three accumulation areas and realize that the next leg up may come at any time.  Former Eisai investors may soon be moving money over to a device designed to remove the potentially sepsis-inducing cytokines directly via discreet particle size filtering rather than through chemical means.  This may be just enough catalyst to force the chart up another leg where it will possibly stay while investors await the press release announcing the long-anticipated trial completion.

     As of November 2010, 85 of the targeted 100 patients in Cytosorbent’s European sepsis trial had been treated, so we’re looking at the completion of the trial likely to be announced any day now.  With a chart trending up sharply and a nice convergence in the chart coming soon, traders and investors alike will be watching this microcap company come into its own in the medical device world.  The medical community’s, traders’ and investors’ expectations are high for Cytosorbents, so we have great anticipation of CE Mark  regulatory approval in Europe coming soon.  If all goes well with this trial, we’ll likely see trials in the United States soon thereafter.  For a company with a current market cap of approximately 17.1 million dollars, a potential blockbuster device will certainly give more than just moderate gains to those holding the precious shares of CTSO.


    For an in-depth explanation of the cytosorbent filter technology, please refer to my previous article http://seekingalpha.com/instablog/399559-chemistfrog/78833-cytosorb-is-a-novel-application-of-tried-and-true-technology.


    Additionally, please read the following excerpt from the Eisai announcement of its now-failed phase III Eritoran trial to put things into perspective pertaining to the significance of an approved cytokine filter (an overabundance of cytokines produced to fight off infection is thought to induce sepsis).


    http://www.fiercebiotech.com/press-releases/eisai-phase-iii-study-eritoran-does-not-meet-primary-endpoint

     
    “Each year, severe sepsis causes approximately 215,000 deaths in the United States - as many as heart attacks, and nearly as many as lung, colorectal and breast cancers combined -- with a mortality rate of approximately 30 percent (depending on the population studied). Worldwide, sepsis affects 18 million people every year. The incidence of severe sepsis in the European Union has been estimated at 90.4 cases per 100,000 population, with a mortality of 36 percent. The incidence of severe sepsis in Japan is estimated at more than 380,000 cases per year.

Back To Chemistfrog's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (5)
Track new comments
  • austinm3
    , contributor
    Comments (2) | Send Message
     
    Correction to "As of November 2010, 85 of the targeted 100": At the end of November, they announced an additional 5 patients enrolled bringing the tally to 90. That was in an update over 2 months ago.
    26 Jan 2011, 09:46 AM Reply Like
  • Chemistfrog
    , contributor
    Comments (285) | Send Message
     
    Author’s reply » Thanks Austin. You're correct. By the way, do you have a quick link? If not, I'll try to find it and post it later.

     

    Thanks and good luck!
    Chemistfrog
    27 Jan 2011, 10:11 PM Reply Like
  • PhD.Euiler
    , contributor
    Comments (2) | Send Message
     
    Never heard of Cytosorb. Interesting.
    26 Jan 2011, 04:33 PM Reply Like
  • Chemistfrog
    , contributor
    Comments (285) | Send Message
     
    Author’s reply » Thanks for reading. Please read this article I wrote earlier last year on the technology. It's pretty much size exclusion chromatography combined with solid phase extraction cartridges.

     

    seekingalpha.com/insta...
    27 Jan 2011, 10:12 PM Reply Like
  • mark y
    , contributor
    Comments (6) | Send Message
     
    This one looks interesting...certainly has fallen quite a bit from its approval high.
    18 Apr 2011, 08:26 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • Interview With Fabrus President Dr. Vaugh Smider $SNTI http://seekingalpha.com/a/15nnj
    Jan 14, 2014
  • Imminent Catalysts Should Keep Investor Interest Strong For Venaxis In 2014 $APPY http://seekingalpha.com/a/15695
    Dec 30, 2013
  • Been buying safer stocks as of late. Work is too busy to babysit volatile pennies except for very small positions.
    May 22, 2013
More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.